1. Wortman BG, Creutzberg CL, Putter H et al. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 2018; 119: 1067-1074.
2.
Harkenrider MM, Grover S, Erickson BA et al. Vaginal brachytherapy for postoperative endometrial cancer: 2014 Survey of the American Brachytherapy. Brachytherapy 2016; 15: 23-29.
3.
Harkenrider MM, Block AM, Alektiar KM et al. American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review. Brachytherapy 2017; 16: 95-108.
4.
Hoskin P, Hellebust TP, Nout R et al. In: The GEC ESTRO Handbook of Brachytherapy. Second edition. Van Limbergen E, Pötter R, Hoskin P, Baltas D (Eds.). Part II: Clinical practice. ESTRO European Society for treatment Radiation and Oncology, Brussels 2016.
5.
Wortman BG, Astreinidou E, Laman MS et al. PORTEC Study Group Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer. Radiother Oncol 2021; 155: 160-166.
6.
Damast S, Higgins SA, Ratner E et al. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. J Contemp Brachytherapy 2015; 7: 35-40.
7.
Noorian F, Abellana R, Zhang Y et al. Are 7.5 Gy×2 fractions more efficient than 6 Gy×3.in exclusive postoperative endometrial cancer brachytherapy? A clinical and dosimetrical analysis. Radiother Oncol 2023; 189: 109909.
8.
Rovirosa A, Ascaso C, Arenas M et al. Can we shorten the overall treatment time in postoperative brachytherapy of endometrial carcinoma? Comparison of two brachytherapy schedules. Radiother Oncol 2015; 116: 143-148.
9.
Nooriankafshgari F, Abellana R, Zhang Y et al. 68Gy EQD2-(α/β=3) dose constraint to the most exposed 2cm3 of the vagina and vaginal dilator use as main factors impacting vaginal complications in postoperative endometrial cancer treated with external beam irradiation and brachytherapy. Obstetrics and Gynecology and Women’s Health. 2nd edition. J Pers Med 2024; 14: 838.
10.
CTCAE v5.0 incorporates certain elements of the MedDRA terminology. https://www.meddra.org/.
11.
Routledge JA, Burns MP, Swindell R et al. Evaluation of the LENT-SOMA scales for the prospective assessment of treatment morbidity in cervical carcinoma. Int J Radiat Oncol Biol Phys 2003; 56: 502-510.
12.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-1346.
13.
Glatzer M, Tanderup K, Rovirosa A et al. Role of brachytherapy in the postoperative management of endometrial cancer: decision-making analysis among experienced European radiation oncologists. Cancers 2022; 14: 906.
14.
Samper PM, Rovirosa A, Herreros Martínez A et al. Consensus and recommendations on vaginal-cuff Brachytherapy of the Spanish Brachytherapy Groups of SEOR and SEFM. Clin Transl Oncol 2021; 23: 1193-1200.
15.
Pötter R, Tanderup K, Schmid MP et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol 2021; 22: 538-547.
16.
DeCesaris C, Wilson T, Kim J et al. Financial improvements from short course adjuvant vaginal cuff brachytherapy in early endometrial cancer compared with standard of care, “SAVE” Trial. Pract Radiat Oncol 2024: S1879-8500(24)00203-0.
17.
Guinot JL, Pérez-Calatayud J, Azcoaga JM et al. Consensus on treatment of endometrium carcinoma with brachytherapy; SEOR and the SEFM Brachytherapy Groups. Clin Transl Oncol 2012; 14: 263-270.
18.
Zhang Y, Gomez G, Ascaso C et al. Preliminary results of a vaginal constraint for reducing G2 late vaginal complications after postoperative brachytherapy in endometrial cancer: a prospective analysis. Clin Transl Oncol 2022; 24: 875-881.
19.
Aguilera DV, Rovirosa Á, Ascaso C et al. Late G2 vagina toxicity in post-operative endometrial carcinoma is associated with a 68 Gy dose equivalent to 2 Gy per fraction(α/β=3Gy) at 2 cm3 of vagina. Contemp Brachytherapy 2018; 10: 40-46.
20.
Sikorska K, Zolciak-Siwinska A, Kowalczyk A et al. Dosimetric evaluation of vaginal cuff brachytherapy planning in cervical and endometrial cancer patients. J Contemp Brachytherapy 2020; 12: 248-251.
21.
Zhang Y, Rovirosa A, Ascaso C et al. Economic impact of decreasing the fraction number in vaginal cuff brachytherapy: A direct cost analysis. Brachytherapy 2020; 19: 60-65.
22.
Le A, Holmes JA. Changes in receipt of adjuvant brachytherapy for endometrial cancer patients before and after affordable care act: The impact of Medicaid expansion. J Contemp Brachytherapy 2023; 15: 206-211.
